Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2017 | case report

Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel

verfasst von: Ferdinand Haslbauer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Summary

As the prognosis of enteropathy-associated T‑cell lymphoma is poor, innovative treatment options are called for, such as the anti-CD30 monoclonal antibody–drug conjugate brentuximab vedotin. The patient presented in this report was diagnosed with enteropathy-associated T‑cell lymphoma that affected the jejunum. Standard chemotherapy with CHOP induced complete remission, but the disease relapsed within 8 months, with the ileum as the site of relapse. Since further testing revealed CD30 positivity, treatment with brentuximab vedotin was started. After 18 cycles, the treatment had to be discontinued owing to another condition that required surgery, upon which the patient relapsed. However, resumption of brentuximab vedotin therapy restored partial remission within 3 months.
Vorheriger Artikel Orbito-maxillofacial mesenchymal chondrosarcoma with intracranial invasion and lung metastasis
Nächster Artikel Primary signet cell carcinoma of the prostate: a case report
Literatur
1.
Okada M, Maeda K, Suzumiya J, et al. Primary colorectal T‑cell lymphoma. J Gastroenterol. 2003;38(3):376–84.CrossRefPubMed
2.
Zinzani PL, Magagnoli M, Pagliani G, et al. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica. 1997;82(3):305–8.PubMed
3.
Swerdlow SH, Campo E, Harris NL. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
4.
Sieniawski MK, Lennard AL. Enteropathy-associated T‑cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011;6(4):231–40.CrossRefPubMed
5.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMedPubMedCentral
6.
Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T‑cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–70.CrossRefPubMed
7.
Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T‑cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87(7):663–8.CrossRefPubMed
8.
Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33:231–5.CrossRefPubMed
9.
Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T‑cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377–84.CrossRefPubMed
10.
Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T‑cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803.CrossRefPubMed
11.
Jantunen E, Boumendil A, Finel H, et al. Autologous stem cell transplantation for enteropathy-associated T‑cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32.CrossRefPubMed
12.
d’Amore F, Relander T, Lauritzsen GF, et al. Upfront autologous stem-cell transplantation in peripheral T‑cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.CrossRefPubMed
13.
Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T‑cell lymphoma: clinical and histological findings from the International Peripheral T‑Cell Lymphoma Project. Blood. 2011;118(1):148–55.CrossRefPubMed
14.
15.
Khalaf WF, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T‑cell lymphoma. J Natl Compr Canc Netw. 2013;11:137–40.CrossRefPubMed
16.
Zelenetz AD, Abramson JS, Advani RH. et al. NCCN Clinical Practice Guidelines in oncology for Non-Hodgkin’s lymphomas. Version 1.2013 2013. NCCN.org. Accessed 16 January 2013.
17.
Grigg-Gutierrez NM, Estremera-Marcial R, Caceres WW, Toro DH. Primary enteropathy-associated T‑cell lymphoma type 2: an emerging entity? Cancer Control. 2015;22(2):242–7.PubMed
18.
Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33(2):231–5.CrossRefPubMed
Metadaten
Titel
Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel
verfasst von
Ferdinand Haslbauer, MD
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0312-x

Weitere Artikel der Ausgabe 2/2017

News in AL Amyloidosis ASH 2016

  • Open Access
  • review

Is there progress in the treatment of high-risk myeloma?

  • short review

American Society of Hematology 2016 annual meeting

  • review

Orbito-maxillofacial mesenchymal chondrosarcoma with intracranial invasion and lung metastasis

  • case report

Short review San Antonio 2016

  • short review

Distinct computed tomography features of non-small-cell lung cancer in a European population with EML4-ALK translocation

  • original report